Hart to Treat Diseases (HTDS) Evaluating Business Proposal
(unsolicited business proposal being evaluated ahead of dividend distribution)
BEIJING, CHINA, Jan. 22 /PRNewswire-FirstCall/ - Jan 22, 2010 -- Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) subsidiary Slavica Bio Chem recently announced entry into the stem cell bank development. An unsolicited business proposal is currently being evaluated by the company from an obstetrician type medical company. This company is engaged in a treatment for pre-term labor and induction of labor. These symptoms affect millions of people worldwide.
HTDS management hopes to build its own stem cell bank and laboratories in Serbia under supervision of its Slavica Biochem medical team and has attracted many inquiries from medical companies. As the issuer has no desire to subscribe to the Pink Sheets filing service a business plan is currently being drafted by the company medical team and will be posted on the company web site in due time.
With these bold projects well underway, HTDS management see great potential in what the other side brings to the table. A source close to the company said, "This medical company from a prosperous Middle Eastern region patented two enzymatic molecules for treatment of labor-related complications. Our understanding is one of the company's patents is pending. The company seeks cooperation with HTDS to co-develop this enzyme and meet GMP and FDA enzyme/cytokines production; as well as to develop Phase II clinical trials in China and share production and marketing with HTDS. Just to put this in perspective, Preterm or premature labor is defined as labor prior to the 37th week of gestation. Preterm birth, a complication that affects 11 percent of births in the U.S.A each year, is responsible for 75% of infant deaths and 50% of the long-term neurological handicaps, including cerebral palsy, blindness, deafness, and developmental defects. The direct cost of care in Neonatal Intensive Care Units (NICU) is a staggering $45 billion to $65 billion in the Western world, treating an estimated 1.5 million preterm babies, and totalling about 4.5 million NICU hospitalization weeks.
"The candidate doesn't wish to share any detailed information at this stage of negotiations. HTDS management is offering this general overview of the business under consideration."
The company brings attention to its filings on Pink Sheets of November 24 2009 http://www.pinksheets.com/otciq/ajax/showFinancialReportById.pdf?id=26604 and confirms that this aforementioned obstetrician type medical company is non related to the regenerative medicine project which are separate and unrelated. With the regenerative medicine project the due diligence continues. The company management feels that this entire update is a material event of which its followers should be made aware.
To be included in HTDS' email database for press releases and industry updates, please subscribe at or opt in with your email address at this link: http://www.minamargroup.com/updates/.
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiries only, please contact firstname.lastname@example.org; for any corporate matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases